← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Starlight Cardiovascular, Inc.
San Diego, CA
$6,687,025
Total funding
5
Grants
Funding over time
peak $2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,687,025 · 5
By mechanism
R44$5,246,454 · 2
R43$940,571 · 2
SB1$500,000 · 1
Investigators at Starlight Cardiovascular, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$1,256,635
R44 · FY2022 · HL
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$999,969
R44 · FY2024 · HL
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$999,918
R44 · FY2025 · HL
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$999,901
R44 · FY2025 · HL
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$901,548
R44 · FY2023 · HL
Commercialization Readiness for Ductus Arteriosus Stent to Improve Congenital Heart Defect Mortality$500,000
SB1 · FY2024 · HL
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$492,571
R43 · FY2021 · HL
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$448,000
R43 · FY2022 · HL
Administrative Supplement to Promote Diversity in MedTech Through Development of Pulmonary Flow Restrictors$88,483
R44 · FY2024 · HL